世界の有毛細胞白血病治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Hairy Cell Leukemia Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12311 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、84ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、有毛細胞白血病治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。有毛細胞白血病治療の種類別市場規模（デザペリシブ、ELB-021、イブルチニブ、AGS-67E、ARABS-4、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・有毛細胞白血病治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AbbVie Inc、ARA Healthcare Pvt Ltd、Astellas Pharma Inc.、Cellectis SA、F. Hoffmann-La Roche Ltd、Incyte Corp、Juno Therapeutics Inc、MedImmune LLC、Novartis AG ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：デザペリシブ、ELB-021、イブルチニブ、AGS-67E、ARABS-4、その他 ・用途別分析2016年-2026年：病院、クリニック、その他 ・有毛細胞白血病治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・有毛細胞白血病治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・有毛細胞白血病治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・有毛細胞白血病治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・有毛細胞白血病治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Hairy Cell Leukemia Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Hairy Cell Leukemia Therapeutics size is estimated to be USD 105.3 million in 2026 from USD 88 million in 2020, with a change XX% between 2020 and 2021. The global Hairy Cell Leukemia Therapeutics market size is expected to grow at a CAGR of 4.6% for the next five years.

Market segmentation
Hairy Cell Leukemia Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Dezapelisib
ELB-021
Ibrutinib
AGS-67E
ARABS-4
Others

Market segment by Application, can be divided into
Hospital
Clinic
Others

Market segment by players, this report covers
AbbVie Inc
ARA Healthcare Pvt Ltd
Astellas Pharma Inc.
Cellectis SA
F. Hoffmann-La Roche Ltd
Incyte Corp
Juno Therapeutics Inc
MedImmune LLC
Novartis AG

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Hairy Cell Leukemia Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Hairy Cell Leukemia Therapeutics, with revenue, gross margin and global market share of Hairy Cell Leukemia Therapeutics from 2019 to 2021.
Chapter 3, the Hairy Cell Leukemia Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Hairy Cell Leukemia Therapeutics market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Hairy Cell Leukemia Therapeutics research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Hairy Cell Leukemia Therapeutics
1.2 Classification of Hairy Cell Leukemia Therapeutics by Type
1.2.1 Overview: Global Hairy Cell Leukemia Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Hairy Cell Leukemia Therapeutics Revenue Market Share by Type in 2020
1.2.3 Dezapelisib
1.2.4 ELB-021
1.2.5 Ibrutinib
1.2.6 AGS-67E
1.2.7 ARABS-4
1.2.8 Others
1.3 Global Hairy Cell Leukemia Therapeutics Market by Application
1.3.1 Overview: Global Hairy Cell Leukemia Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Hairy Cell Leukemia Therapeutics Market Size & Forecast
1.5 Global Hairy Cell Leukemia Therapeutics Market Size and Forecast by Region
1.5.1 Global Hairy Cell Leukemia Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Hairy Cell Leukemia Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Hairy Cell Leukemia Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Hairy Cell Leukemia Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Hairy Cell Leukemia Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Hairy Cell Leukemia Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Hairy Cell Leukemia Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Hairy Cell Leukemia Therapeutics Market Drivers
1.6.2 Hairy Cell Leukemia Therapeutics Market Restraints
1.6.3 Hairy Cell Leukemia Therapeutics Trends Analysis
2 Company Profiles
2.1 AbbVie Inc
2.1.1 AbbVie Inc Details
2.1.2 AbbVie Inc Major Business
2.1.3 AbbVie Inc Hairy Cell Leukemia Therapeutics Product and Solutions
2.1.4 AbbVie Inc Hairy Cell Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AbbVie Inc Recent Developments and Future Plans
2.2 ARA Healthcare Pvt Ltd
2.2.1 ARA Healthcare Pvt Ltd Details
2.2.2 ARA Healthcare Pvt Ltd Major Business
2.2.3 ARA Healthcare Pvt Ltd Hairy Cell Leukemia Therapeutics Product and Solutions
2.2.4 ARA Healthcare Pvt Ltd Hairy Cell Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 ARA Healthcare Pvt Ltd Recent Developments and Future Plans
2.3 Astellas Pharma Inc.
2.3.1 Astellas Pharma Inc. Details
2.3.2 Astellas Pharma Inc. Major Business
2.3.3 Astellas Pharma Inc. Hairy Cell Leukemia Therapeutics Product and Solutions
2.3.4 Astellas Pharma Inc. Hairy Cell Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Astellas Pharma Inc. Recent Developments and Future Plans
2.4 Cellectis SA
2.4.1 Cellectis SA Details
2.4.2 Cellectis SA Major Business
2.4.3 Cellectis SA Hairy Cell Leukemia Therapeutics Product and Solutions
2.4.4 Cellectis SA Hairy Cell Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Cellectis SA Recent Developments and Future Plans
2.5 F. Hoffmann-La Roche Ltd
2.5.1 F. Hoffmann-La Roche Ltd Details
2.5.2 F. Hoffmann-La Roche Ltd Major Business
2.5.3 F. Hoffmann-La Roche Ltd Hairy Cell Leukemia Therapeutics Product and Solutions
2.5.4 F. Hoffmann-La Roche Ltd Hairy Cell Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.6 Incyte Corp
2.6.1 Incyte Corp Details
2.6.2 Incyte Corp Major Business
2.6.3 Incyte Corp Hairy Cell Leukemia Therapeutics Product and Solutions
2.6.4 Incyte Corp Hairy Cell Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Incyte Corp Recent Developments and Future Plans
2.7 Juno Therapeutics Inc
2.7.1 Juno Therapeutics Inc Details
2.7.2 Juno Therapeutics Inc Major Business
2.7.3 Juno Therapeutics Inc Hairy Cell Leukemia Therapeutics Product and Solutions
2.7.4 Juno Therapeutics Inc Hairy Cell Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Juno Therapeutics Inc Recent Developments and Future Plans
2.8 MedImmune LLC
2.8.1 MedImmune LLC Details
2.8.2 MedImmune LLC Major Business
2.8.3 MedImmune LLC Hairy Cell Leukemia Therapeutics Product and Solutions
2.8.4 MedImmune LLC Hairy Cell Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 MedImmune LLC Recent Developments and Future Plans
2.9 Novartis AG
2.9.1 Novartis AG Details
2.9.2 Novartis AG Major Business
2.9.3 Novartis AG Hairy Cell Leukemia Therapeutics Product and Solutions
2.9.4 Novartis AG Hairy Cell Leukemia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Novartis AG Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Hairy Cell Leukemia Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Hairy Cell Leukemia Therapeutics Players Market Share
3.2.2 Top 10 Hairy Cell Leukemia Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Hairy Cell Leukemia Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Hairy Cell Leukemia Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Hairy Cell Leukemia Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Hairy Cell Leukemia Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Hairy Cell Leukemia Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Hairy Cell Leukemia Therapeutics Revenue by Type (2016-2026)
6.2 North America Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2026)
6.3 North America Hairy Cell Leukemia Therapeutics Market Size by Country
6.3.1 North America Hairy Cell Leukemia Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Hairy Cell Leukemia Therapeutics Revenue by Type (2016-2026)
7.2 Europe Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2026)
7.3 Europe Hairy Cell Leukemia Therapeutics Market Size by Country
7.3.1 Europe Hairy Cell Leukemia Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Hairy Cell Leukemia Therapeutics Market Size by Region
8.3.1 Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue by Region (2016-2026)
8.3.2 China Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Hairy Cell Leukemia Therapeutics Revenue by Type (2016-2026)
9.2 South America Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2026)
9.3 South America Hairy Cell Leukemia Therapeutics Market Size by Country
9.3.1 South America Hairy Cell Leukemia Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Hairy Cell Leukemia Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Hairy Cell Leukemia Therapeutics Market Size by Country
10.3.1 Middle East & Africa Hairy Cell Leukemia Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Hairy Cell Leukemia Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Hairy Cell Leukemia Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Hairy Cell Leukemia Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Hairy Cell Leukemia Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Hairy Cell Leukemia Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Hairy Cell Leukemia Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. AbbVie Inc Corporate Information, Head Office, and Major Competitors
Table 7. AbbVie Inc Major Business
Table 8. AbbVie Inc Hairy Cell Leukemia Therapeutics Product and Solutions
Table 9. AbbVie Inc Hairy Cell Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. ARA Healthcare Pvt Ltd Corporate Information, Head Office, and Major Competitors
Table 11. ARA Healthcare Pvt Ltd Major Business
Table 12. ARA Healthcare Pvt Ltd Hairy Cell Leukemia Therapeutics Product and Solutions
Table 13. ARA Healthcare Pvt Ltd Hairy Cell Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Astellas Pharma Inc. Corporate Information, Head Office, and Major Competitors
Table 15. Astellas Pharma Inc. Major Business
Table 16. Astellas Pharma Inc. Hairy Cell Leukemia Therapeutics Product and Solutions
Table 17. Astellas Pharma Inc. Hairy Cell Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Cellectis SA Corporate Information, Head Office, and Major Competitors
Table 19. Cellectis SA Major Business
Table 20. Cellectis SA Hairy Cell Leukemia Therapeutics Product and Solutions
Table 21. Cellectis SA Hairy Cell Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. F. Hoffmann-La Roche Ltd Corporate Information, Head Office, and Major Competitors
Table 23. F. Hoffmann-La Roche Ltd Major Business
Table 24. F. Hoffmann-La Roche Ltd Hairy Cell Leukemia Therapeutics Product and Solutions
Table 25. F. Hoffmann-La Roche Ltd Hairy Cell Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Incyte Corp Corporate Information, Head Office, and Major Competitors
Table 27. Incyte Corp Major Business
Table 28. Incyte Corp Hairy Cell Leukemia Therapeutics Product and Solutions
Table 29. Incyte Corp Hairy Cell Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Juno Therapeutics Inc Corporate Information, Head Office, and Major Competitors
Table 31. Juno Therapeutics Inc Major Business
Table 32. Juno Therapeutics Inc Hairy Cell Leukemia Therapeutics Product and Solutions
Table 33. Juno Therapeutics Inc Hairy Cell Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. MedImmune LLC Corporate Information, Head Office, and Major Competitors
Table 35. MedImmune LLC Major Business
Table 36. MedImmune LLC Hairy Cell Leukemia Therapeutics Product and Solutions
Table 37. MedImmune LLC Hairy Cell Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 39. Novartis AG Major Business
Table 40. Novartis AG Hairy Cell Leukemia Therapeutics Product and Solutions
Table 41. Novartis AG Hairy Cell Leukemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Global Hairy Cell Leukemia Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 43. Global Hairy Cell Leukemia Therapeutics Revenue Share by Players (2019-2021)
Table 44. Breakdown of Hairy Cell Leukemia Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Hairy Cell Leukemia Therapeutics Players Head Office, Products and Services Provided
Table 46. Hairy Cell Leukemia Therapeutics Mergers & Acquisitions in the Past Five Years
Table 47. Hairy Cell Leukemia Therapeutics New Entrants and Expansion Plans
Table 48. Global Hairy Cell Leukemia Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 49. Global Hairy Cell Leukemia Therapeutics Revenue Share by Type (2016-2021)
Table 50. Global Hairy Cell Leukemia Therapeutics Revenue Forecast by Type (2021-2026)
Table 51. Global Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2021)
Table 52. Global Hairy Cell Leukemia Therapeutics Revenue Forecast by Application (2021-2026)
Table 53. North America Hairy Cell Leukemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 54. North America Hairy Cell Leukemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 55. North America Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 56. North America Hairy Cell Leukemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 57. North America Hairy Cell Leukemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 58. North America Hairy Cell Leukemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 59. Europe Hairy Cell Leukemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 60. Europe Hairy Cell Leukemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 61. Europe Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 62. Europe Hairy Cell Leukemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 63. Europe Hairy Cell Leukemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 64. Europe Hairy Cell Leukemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 65. Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 66. Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 67. Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 68. Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 69. Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 70. Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 71. South America Hairy Cell Leukemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 72. South America Hairy Cell Leukemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 73. South America Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 74. South America Hairy Cell Leukemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 75. South America Hairy Cell Leukemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 76. South America Hairy Cell Leukemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Hairy Cell Leukemia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 78. Middle East & Africa Hairy Cell Leukemia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 79. Middle East & Africa Hairy Cell Leukemia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 80. Middle East & Africa Hairy Cell Leukemia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 81. Middle East & Africa Hairy Cell Leukemia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 82. Middle East & Africa Hairy Cell Leukemia Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Hairy Cell Leukemia Therapeutics Picture
Figure 2. Global Hairy Cell Leukemia Therapeutics Revenue Market Share by Type in 2020
Figure 3. Dezapelisib
Figure 4. ELB-021
Figure 5. Ibrutinib
Figure 6. AGS-67E
Figure 7. ARABS-4
Figure 8. Others
Figure 9. Hairy Cell Leukemia Therapeutics Revenue Market Share by Application in 2020
Figure 10. Hospital Picture
Figure 11. Clinic Picture
Figure 12. Others Picture
Figure 13. Global Hairy Cell Leukemia Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Hairy Cell Leukemia Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Hairy Cell Leukemia Therapeutics Revenue Market Share by Region (2016-2026)
Figure 16. Global Hairy Cell Leukemia Therapeutics Revenue Market Share by Region in 2020
Figure 17. North America Hairy Cell Leukemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Hairy Cell Leukemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Hairy Cell Leukemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Middle East and Africa Hairy Cell Leukemia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Hairy Cell Leukemia Therapeutics Market Drivers
Figure 23. Hairy Cell Leukemia Therapeutics Market Restraints
Figure 24. Hairy Cell Leukemia Therapeutics Market Trends
Figure 25. AbbVie Inc Recent Developments and Future Plans
Figure 26. ARA Healthcare Pvt Ltd Recent Developments and Future Plans
Figure 27. Astellas Pharma Inc. Recent Developments and Future Plans
Figure 28. Cellectis SA Recent Developments and Future Plans
Figure 29. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
Figure 30. Incyte Corp Recent Developments and Future Plans
Figure 31. Juno Therapeutics Inc Recent Developments and Future Plans
Figure 32. MedImmune LLC Recent Developments and Future Plans
Figure 33. Novartis AG Recent Developments and Future Plans
Figure 34. Global Hairy Cell Leukemia Therapeutics Revenue Share by Players in 2020
Figure 35. Hairy Cell Leukemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Hairy Cell Leukemia Therapeutics Revenue Market Share in 2020
Figure 37. Global Top 10 Players Hairy Cell Leukemia Therapeutics Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Hairy Cell Leukemia Therapeutics Revenue Share by Type in 2020
Figure 40. Global Hairy Cell Leukemia Therapeutics Market Share Forecast by Type (2021-2026)
Figure 41. Global Hairy Cell Leukemia Therapeutics Revenue Share by Application in 2020
Figure 42. Global Hairy Cell Leukemia Therapeutics Market Share Forecast by Application (2021-2026)
Figure 43. North America Hairy Cell Leukemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 44. North America Hairy Cell Leukemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 45. North America Hairy Cell Leukemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 46. United States Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Hairy Cell Leukemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 50. Europe Hairy Cell Leukemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 51. Europe Hairy Cell Leukemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 52. Germany Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Hairy Cell Leukemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Hairy Cell Leukemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Hairy Cell Leukemia Therapeutics Revenue Market Share by Region (2016-2026)
Figure 60. China Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Hairy Cell Leukemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 67. South America Hairy Cell Leukemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 68. South America Hairy Cell Leukemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Hairy Cell Leukemia Therapeutics Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Hairy Cell Leukemia Therapeutics Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Hairy Cell Leukemia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Hairy Cell Leukemia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source

---